amoxicillin + clarithromycin or amoxicillin + furazolidone

This entry refers to two alternative combination regimens used primarily for the eradication of Helicobacter pylori infection, a common cause of peptic ulcer disease. The first regimen combines amoxicillin (a beta-lactam antibiotic) with clarithromycin (a macrolide antibiotic), while the second combines amoxicillin with furazolidone (a nitrofuran antibacterial agent). Both regimens are typically administered alongside a proton pump inhibitor (such as omeprazole or lansoprazole) to increase gastric pH and enhance antibiotic efficacy. - **Amoxicillin** acts by inhibiting bacterial cell wall synthesis. - **Clarithromycin** inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit. - **Furazolidone** interferes with bacterial enzyme systems, exhibiting broad-spectrum antibacterial activity and also functions as a monoamine oxidase inhibitor. These combinations are chosen based on local patterns of antibiotic resistance, cost considerations, and patient tolerance. Clarithromycin-based triple therapy is widely used but may be less effective in areas with high clarithromycin resistance or where cost is prohibitive. Furazolidone-based regimens serve as alternatives in such settings but can have more frequent side effects[6][8][10].